Invitrogen Enters Non-Coding RNA Licensing Agreement with IMBcom

Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, has entered into an exclusive license agreement with IMBcom Proprietary Limited Company to commercialize new non-coding ribonucleic acid (RNA) content predicted by a proprietary algorithm and experimentally validated by the University of Queensland, Australia. This expanded content will enable Invitrogen to provide the most comprehensive non-coding RNA product portfolio in the market and be the first company to provide this new content to the research community.

"MicroRNAs, which are the focus of current non-coding RNA research, are just one small subset of the non-coding RNA world," said Peter Welch director of research and development for Gene Expression Profiling at Invitrogen. "MicroRNAs have a discrete function in gene regulation, but the larger non-coding RNAs are involved in multiple roles such as cellular aging and protein assembly, in addition to simple gene regulation."

By combining the coding and non-coding sequences on the same microarray, researchers can obtain more information from a single sample to better reveal the relationship between non-coding RNA expression and mRNA expression. This is particularly important for scientists studying cancer and stem cells, for such RNAs have been implicated in both of these areas.

Researchers at the University of Queensland developed an algorithm that has predicted tens of thousands of unique human and mouse probe sequences relating to coding and non-coding RNA.

John Mattick, professor of Molecular Biology at the University of Queensland added, "It appears that we have misunderstood the nature of genetic programming in humans and other complex organisms. Most of the genome is transcribed, mainly into non-coding RNAs, which appear to comprise a hidden layer of gene regulation whose full dimensions are just beginning to be explored."

Invitrogen will commercialize these sequences over the next few years, allowing the company to expand its NCode(TM) microRNA microarray product line into the field of non-coding RNA profiling. Thus, for the first time, a commercial tool will be available to help scientists to identify the large complement of non-coding RNAs and study their function.

For more information, visit: www.invitrogen.com/ncode or www.imbcom.com.au.

About Invitrogen

Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of more than $1.15 billion in 2006. For more information, visit www.invitrogen.com.

About IMBcom Pty Ltd

IMBcom is The University of Queensland's company for commercialisation of the intellectual property arising from research conducted at The Institute for Molecular Bioscience (IMB).